← Back to Analyst Consensus 
COGT Buy
Cogent Biosciences, Inc.
Current Price —
Implied Upside —
Analysts 18
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Next Earnings
Nov 10, 2026 (14 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Sep 16, 2026 | Wedbush | reiterate | Outperform → Outperform | — | 57% |
| Sep 15, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Aug 17, 2026 | Piper Sandler | maintain | Overweight → Overweight | — | 54% |
| Aug 12, 2026 | Guggenheim | maintain | Buy → Buy | — | 52% |
| May 29, 2026 | Wedbush | reiterate | Outperform → Outperform | — | 57% |
| May 6, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Mar 17, 2026 | Wedbush | reiterate | Outperform → Outperform | — | 57% |
| Feb 18, 2026 | Piper Sandler | maintain | Overweight → Overweight | $52 | 54% |
| Jan 21, 2026 | Wedbush | reiterate | Outperform → Outperform | $55 | 57% |
| Jan 6, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | $52 | 44% |
| Dec 19, 2025 | JP Morgan | maintain | Overweight → Overweight | $67 | 55% |
| Dec 8, 2025 | Needham | reiterate | Hold → Hold | $0 | 50% |
| Nov 13, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $50 | 44% |
| Nov 11, 2025 | Baird | maintain | Neutral → Neutral | $34 | 55% |
| Nov 10, 2025 | Leerink Partners | maintain | Outperform → Outperform | $50 | 51% |
| Nov 4, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $21 | 44% |
| Oct 21, 2025 | JP Morgan | maintain | Overweight → Overweight | $44 | 55% |
| Oct 16, 2025 | Stifel | initiate | — → Hold | $16 | 53% |
| Sep 3, 2025 | Raymond James | initiate | — → Strong Buy | $30 | 53% |
| Aug 25, 2025 | Guggenheim | maintain | Buy → Buy | $20 | 52% |
| Aug 7, 2025 | JP Morgan | maintain | Overweight → Overweight | $30 | 55% |
| Aug 6, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $21 | 44% |
| Jul 18, 2025 | Citigroup | maintain | Buy → Buy | $22 | 54% |
| Jul 10, 2025 | JP Morgan | maintain | Overweight → Overweight | $29 | 55% |
| Jul 8, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $22 | 44% |
| Jul 8, 2025 | Guggenheim | reiterate | Buy → Buy | $17 | 52% |
| Jul 8, 2025 | Baird | maintain | Neutral → Neutral | $9 | 55% |
| Jul 7, 2025 | Leerink Partners | maintain | Outperform → Outperform | $18 | 51% |
| Jul 7, 2025 | Jefferies | maintain | Buy → Buy | $28 | 52% |
| Jun 17, 2025 | Needham | reiterate | Hold → Hold | $0 | 50% |
| May 29, 2025 | JP Morgan | maintain | Overweight → Overweight | $25 | 55% |
| May 20, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $12 | 44% |
| May 7, 2025 | Baird | maintain | Neutral → Neutral | $7 | 55% |
| Mar 7, 2025 | Scotiabank | initiate | — → Sector Outperform | $17 | 55% |
| Feb 27, 2025 | Baird | maintain | Neutral → Neutral | $8 | 55% |
| Feb 26, 2025 | Needham | reiterate | Hold → Hold | $0 | 50% |
| Jan 14, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $14 | 44% |
| Dec 11, 2024 | Needham | downgrade | Buy → Hold | $15 | 50% |
| Dec 11, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $0 | 44% |
| Dec 10, 2024 | Needham | reiterate | Buy → Buy | $15 | 50% |
| Dec 9, 2024 | Needham | reiterate | Buy → Buy | $15 | 50% |
| Nov 14, 2024 | JP Morgan | maintain | Overweight → Overweight | $21 | 55% |
| Nov 13, 2024 | Needham | maintain | Buy → Buy | $15 | 50% |
| Nov 4, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $17 | 44% |
| Oct 24, 2024 | Needham | reiterate | Buy → Buy | $16 | 50% |
| Sep 24, 2024 | Citigroup | maintain | Buy → Buy | $15 | 54% |
| Sep 5, 2024 | Baird | maintain | Neutral → Neutral | $10 | 55% |
| Sep 3, 2024 | HC Wainwright & Co. | maintain | Buy → Buy | $17 | 44% |
| Aug 7, 2024 | JP Morgan | maintain | Overweight → Overweight | $19 | 55% |
| Aug 7, 2024 | Needham | reiterate | Buy → Buy | $18 | 50% |
Price Target Trend
Jun 4, 2026 Oct 27, 2026
EPS Estimates
+1q —
0q —
+1y —
0y —
Cross-Platform Signals
No cross-platform signals in the last 90 days